- Home
- SORA vs ELUT Comparison
SORA vs ELUT Comparison
Compare SORA & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SORA | ELUT |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | Hong Kong | United States |
| Employees | 7 | N/A |
| Industry | Other Specialty Stores | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.5M | 46.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SORA | ELUT |
|---|---|---|
| Price | $1.85 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 6.3K | ★ 193.2K |
| Earning Date | 01-01-0001 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | N/A | ★ 0.87 |
| Revenue | N/A | ★ $12,293,000.00 |
| Revenue This Year | N/A | $26.95 |
| Revenue Next Year | N/A | $24.84 |
| P/E Ratio | ★ N/A | $1.24 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.57 | $0.50 |
| 52 Week High | $10.27 | $3.46 |
Technical Indicators
Market Signals| Indicator | SORA | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 52.62 |
| Support Level | $1.76 | $0.86 |
| Resistance Level | $3.08 | $1.15 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 21.79 | 31.25 |
Price Performance
Historical ComparisonAbout SORA Top Win International Limited Ordinary Shares
AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.